Skip to main content
. 2019 Jan 30;9(4):1047–1065. doi: 10.7150/thno.29820

Figure 4.

Figure 4

Antitumor effects of Pt(IV) NP-cRGD under US exposure in vitro. (A) Cell viability of the SKOV3 cells treated with various concentrations of cisplatin, Pt(IV), Pt(IV) NPs, Pt(IV) NPs+US, Pt(IV) NP-cRGD and Pt(IV) NP-cRGD+US for 48 h. (B) Fluorescence images and (C) quantitative fluorescence intensity of Calcein-AM in the SKOV3 cells treated with NP-cRGD+US, cisplatin, Pt(IV), Pt(IV) NPs, Pt(IV) NPs+US, Pt(IV) NP-cRGD and Pt(IV) NP-cRGD+US (containing an equal amount of 30 μM platinum) for 48 h. Original magnification, 100×; Scale bar 200 μm. (D) Flow cytometric analysis and (E) CLSM images of SKOV3 cells treated with free RB, RB NPs, RB NP-cRGD and RB NP-cRGD+US for 1 h and 4 h, RB: Rhodamine B. The cells were incubated with the respective nanoparticle solutions (20 μg/mL RB) for 1 h and 4 h. All pictures show merged images, which include the nuclei (blue) and nanoparticles (red). Scale bar 20 μm. The data are presented as the mean ± SD of three independent experiments. Statistical significance in (C) was calculated by one-way ANOVA with Tukey's post hoc test. *P < 0.05, **P < 0.01, ***P < 0.005, NS indicates P > 0.05.